Core Viewpoint - The company has received notifications from health authorities in Shanxi and Jiangsu provinces regarding the suspension of its Phase III clinical trials for both the trivalent and nine-valent human papillomavirus (HPV) vaccines due to overdue funding for clinical trial expenses [1] Group 1 - The Shanxi Provincial Center for Disease Control and Prevention has suspended the Phase III clinical trials for the company's trivalent HPV vaccine [1] - The Jiangsu Provincial Center for Disease Control and Prevention has also suspended the Phase III clinical trials for the company's nine-valent HPV vaccine [1] - The suspensions are attributed to the company's inability to continue subsequent gynecological visits due to a shortage of funding for on-site research expenses [1]